Treating advanced hepatocellular carcinoma: How to get out of first gear Journal Article
| Authors: | Harding, J. J.; Abou-Alfa, G. K. |
| Article Title: | Treating advanced hepatocellular carcinoma: How to get out of first gear |
| Abstract: | Hepatocellular carcinoma is a common malignancy with a poor prognosis. Sorafenib is the only systemic therapy known to improve the overall survival of patients with advanced disease. The clinical benefit of sorafenib is modest and the mechanistic basis for its activity is unknown. Four phase 3 clinical trials have failed to improve on sorafenib in the frontline setting and no agent has been shown to impact outcomes after sorafenib failure. Several factors have contributed to this recent stall in drug development but new approaches hold promise and currently are being investigated. This review will focus on the current pipeline of experimental therapeutics for patients with advanced hepatocellular carcinoma and shed a light on scientific limitations that hamper the advancement of new therapies for this disease, and ways around it. |
| Keywords: | mitogen activated protein kinase; protein kinase b; vasculotropin; vasculotropin receptor 3; cancer survival; protein expression; treatment response; gene mutation; overall survival; drug tolerability; review; hepatocellular carcinoma; sorafenib; bevacizumab; doxorubicin; erlotinib; sunitinib; advanced cancer; cancer growth; drug efficacy; liver cell carcinoma; nonhuman; pathophysiology; ticilimumab; unindexed drug; vasculotropin receptor; progression free survival; protein metabolism; antineoplastic activity; vasculotropin receptor 2; angiogenesis; temsirolimus; scatter factor; drug fatality; liver metastasis; immunotherapy; mammalian target of rapamycin; antiangiogenic therapy; targeted therapy; inoperable cancer; drug half life; hepatitis c virus; primary medical care; everolimus; ethnicity; arginine; angiogenic; randomized controlled trial (topic); brivanib; tremelimumab; azd 8055; cabozantinib; regorafenib; tivantinib; linifanib; foretinib; ramucirumab; human; pegylated arginine deiminase (adi-peg 20); emibetuzumab; golvatinib; onartuzumab; pegargiminase |
| Journal Title: | Cancer |
| Volume: | 120 |
| Issue: | 20 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2014-10-15 |
| Start Page: | 3122 |
| End Page: | 3130 |
| Language: | English |
| DOI: | 10.1002/cncr.28850 |
| PROVIDER: | scopus |
| PUBMED: | 24898783 |
| DOI/URL: | |
| Notes: | Export Date: 1 December 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work